Asthma and COPD Pharmacology

0.0(0)
Studied by 0 people
call kaiCall Kai
learnLearn
examPractice Test
spaced repetitionSpaced Repetition
heart puzzleMatch
flashcardsFlashcards
GameKnowt Play
Card Sorting

1/41

encourage image

There's no tags or description

Looks like no tags are added yet.

42 Terms

1
New cards

Asthma

PP: airway inflammation+hyperresponsiveness

CM+DX: wheeze
SOB
cough
chest tightness
+
confirmed variable expiratory airflow limitation
-FEV1→reduced
-PFT→excessive variability in lung fxn

2
New cards

Asthma Assessment

asthma control

tx issues
inhaler technique
adherence
side effects
attitude towards tx

comorbidities
rhinitis
rhinosinusitis
GERD
obesity
OSA
depression
anxiety

3
New cards

Asthma Tx Format

1st line/preferred→track 1

  • 1+2: inhaled budesonide/fluticasone+formoterol PRN
    -sxs u4-5 days/week

  • 3: low-dose budesonide/fluticasone+formoterol MART

  • 4: medium-dose budesonide/fluticasone+formoterol

  • 5: add tiotropium
    pulmonary referral
    high-dose budesonide/fluticasone+formoterol
    anti-IgE
    anti-IL5/5R
    anti-IL4Ra
    anti-TSLP

reliever→low-dose budesonide/fluticasone+formoterol PRN

track 2

  • 1: budesonide/fluticasone+albuterol PRN
    -sxs u 2 times/month

  • 2: low-dose budesonide/fluticasone
    -sxs u 2 times/month<x<4-5 days/week

  • 3: low-dose budesonide/fluticasone+formoterol/salmeterol

  • 4: medium-dose budesonide/fluticasone+formoterol/salmeterol

  • 5: add tiotropium
    pulm referral
    high-dose budesonide/fluticasone+formoterol/salmeterol
    anti-IgE
    anti-IL5/5R
    anti-IL4Ra
    anti-TSLP

reliever→budesonide/fluticasone+albuterol PRN

4
New cards

Beta-2 Agonists

MX:
short acting (SABA)
albuterol
levalbuterol

long acting (LABA)

Fluticasone propionate (Flovent DISKUS, Flovent)

50 mcg 125 mcg 250 mcg

Salmeterol (Serevent)

50 mcg

Budesonide (Pulmicort Turbuhaler)

100 mcg 200 mcg 400 mcg

Formoterol (Oxeze Turbuhaler)


MOA: relaxes airway smooth muscle

5
New cards

Initiation Step 3

track 1

  • sx x most days
    or
    waking asthma x 1+/week

  • tx→low dose ICS-formoterol+low-dose ICS formoterol reliever PRN

track 2

  • sx x most days
    or
    waking asthma x 1+/week

  • tx→low dose ICS-LABA+SABA reliever PRN


6
New cards

Initiation Step 4

track 1

  • sx x daily
    or
    waking with asthma 1+/week+low lung fxn

  • tx→medium-dose ICS-formoterol+low-dose ICS-formoterol reliever PRN

  • severe+uncontrolled tx→PO corticosteroids

track 2

  • sx x daily
    or
    waking with asthma 1+/week+low lung fxn

  • tx→medium/high-dose ICS-LABA+SABA reliever PRN

  • severe+uncontrolled tx→PO corticosteroids


7
New cards

Initiation Step 5

track 1

  • severely uncontrolled sx

  • exacerbations with tx

  • tx→medium-dose ICS-formoterol+LAMA
    or
    high-dose ICS-formoterol
    refer for phenotype assessment

track 2

  • severely uncontrolled sx

  • exacerbations with tx

  • tx→medium/high dose ICS-LABA+LAMA
    or
    high-dose ICS-LABA
    refer for phenotype assessment


8
New cards

Antimuscarinics

MX:
SAMA
ipatropium

LAMA
glycopyrrolate
umeclidinium
tiotropium
aclidinium
revefenacin

I: COPD

ROA: inhalation

9
New cards

LAMA+LABA+ICS Combinations

MX: umeclinidium+fluticasone+furoate+vilanterol
glycopyrrolate+formoterol+budesonide

I: COPD

ROA: U→daily
G→BID

10
New cards

Asthma Peds Tx (6-11 y/o)

track 1

  1. low-dose ICS+SABA

  2. low-dose inhaled corticosteroid

  3. low-dose ICS-LABA
    or
    medium-dose ICS
    or
    very low-dose ICS-formoterol maintenance and reliever (MART)

  4. medium-dose ICS-LABA
    or
    low-dose ICS formoterol+reliever therapy (MART)

  5. phenotype assessment referral high-dose ICS-LABA
    or
    anti IgE
    or
    anti-IL4R

reliever→SABA/ICS-formoterol reliever (MART)

track 2

  1. low-dose ICS

  2. low-dose ICS+SABA

  3. low dose ICS+LTRA

  4. +biotropium
    or
    +LTRA

  5. +anti-IL5
    or
    low-dose PO corticosteroids

reliever→SABA/ICS-formoterol reliever (MART)

11
New cards

Chronic+Severe Asthma Tx

anti-IgE→omalizumab

anti-IL5/anti-IL5R:
benralizumab
mepolizumab
reslizumab

anti-IL4R→dupilumab

anti-TSLP→tezepelumap

12
New cards

Special Populations: Pregnancy

active tx outweighs side effects

tx exacerbations aggressively

13
New cards

Special Populations: Rhinitis+Sinusitis

associated with more severe asthma

14
New cards

Special Populations: Obesity

more difficult to control

tx plan→add losing weight (5-10%)

15
New cards

Special Populations: Elderly

comorbidities

arthritis

eyesight

inspiratory flow

tx complexity

16
New cards

Special Populations: Gastroesophageal Reflux

common additional/concomitant condition

17
New cards

Special Populations: Anxiety+Depression

help pt distinguish asthma vs anxiety sx

18
New cards

Special Populations: Aspirin-Exacerbated Respiratory Disease

TX: ICX
OCS
LTRA

no: ASA/aspirin
NSAIDS

19
New cards

Special Populations: Food Allergy+Anaphylaxis

rarely trigger for asthma

specialist referral

20
New cards

Special Populations: Surgery

good asthma control needs to be achieved before operation whenever possible

may require intra-operative hydrocortisone→reduce adrenal crisis risk

21
New cards

Asthma Exacerbation Classifications

worsening in sx+lung fxn

mild-moderate

  • talks in phrases

  • prefers sitting-lying

  • not agitated

  • increased RR

  • no accessory muscles

  • HR: 100-120 bpm

  • O2 sat: 90-95%

  • predicted PEF: 50%+

severe

  • talks in words

  • sits hunched forward

  • agitated

  • RR: over 30+ bpm

  • accessory muscle use

  • HR: 120+ bpm

  • O2 sat: u90%

  • predicted PEF: 50%+

life-threatening

  • drowsy

  • confused

  • silent chest


22
New cards

Asthma Exacerbation Tx

mild-moderate
NP: assess for discharge
-improved sx
-no SABA needed
-improving PRF
-O2 sat 94%+
-adequate resources at home
evaluate inhaler technique/adherence

MX: pMDI SABA 4-10 puffs x q20mins for 1hr
prednisolone x 5-7 days
O2 tx

severe/life-threatening/worsening mild-moderate
NP: acute care facility
O2
intubation

MX: nebulized albuterol+ipatropium q4-6h
IV corticosteroids
PO corticosteroids
tx fail→IV magnesium x 1 dose

23
New cards

COPD

PP: persistent respiratory sx
airflow limitation

E: airway abnormalities
alveolar abnormalities
noxious particles
gases
impaired lung growth
lung+systemic infxn

CM: cough
dyspnea
sputum production

DX:
FEV1/FVC→u0.70
inspiratory flow rate→u60L/min
alpha-1 antitrypsin deficiency (AATD)→u20%→deficient variant
-F
-I
-S
-Z
GOLD grade
exacerbation hx
mMRC/CAT

24
New cards

COPD NP Tx+Vaccines

NP:
stop smoking
reduce exposure to irritants/pollutants
pulmonary rehabilitation
O2 tx PRN

Vax:
influenza
SARS-CoV-2
20-valent pneumococcal conjugate
15-valent pneumococcal conjugate+23-valent pneumococcal polysaccharide
tdap
RSV
50+ y/o→zoster

25
New cards

COPD Mx Tx

0-1 moderate exacerbations+no hospitalization
mMRC 0-1/CAT u10→A bronchodilator
mMRC 2+/CAT 10+→LABA+LAMA

2+ moderate exacerbation/1+hospitalization
LABA+LAMA
blood eos 300+→LABA+LAMA+ICS

26
New cards

Bronchodilators (General)

increase FEV1

change other spirometric variables

alter airway smooth muscle→widen airways→improve expiratory flow

reduce dynamic hyperinflation

improve exercise tolerance

MX
beta2 agonists
antimuscarinics
methylxanthines

27
New cards

Beta 2 Agonists

MX:
short acting beta2 agonists (SABA)
albuterol
levalbuterol

long acting beta2 agonists (LABA)
formoterol
aformoterol

indacaterol
salmeterol
olodaterol

MOA: stimulates beta2 adrenergic receptors→increases cyclic AMP→antagonizes bronchoconstriction→relaxes smooth muscle of airway

I: COPD
formoterol→COPD+asthma

ROA:
SABA
1-2 inhalations q4-6 hrs PRN

LABA
F+AF+S→BID
I→daily
O→twice daily

duration
short acting beta2 agonists (SABA)→4-6hrs
long acting beta2 agonists (LABA)→12-24hrs

AE: resting sinus tachycardia
precipitate arrhythmias
BP increased
glucose increased
IOP increased
hypokalemia
CNS simulation/excitation→seizures

28
New cards

Antimuscarinics

MX:
short-acting antimuscarinics (SAMA)
ipatropium

long-acting antimuscarinics (LAMA)
glycopyrrolate
umeclidinium
tiotropium
aclidinium
revefenacin

SAMA-SABA combination
ipatropium bromide-albuterol

LAMA-LABA combination
umeclidinium-vilanterol
glycopyrrolate-formoterol fumarate
tiotropium bromide-olodaterol
indacterol-glycopyrrolate inhalation

MOA: blocks bronchoconstrictor effects of acetylcholine on M3 muscarinic receptors→bronchodilation
blocks inhibitory neuronal receptor M2→vagally-induced bronchoconstriction
located on bronchial smooth muscle

I: COPD

ROA:
short-acting antimuscarinics (SAMA)
more pronounced effect on M2
2 inhalations QID

long-acting antimuscarinics (LAMA)
prolonged binding to M3→longer duration
dissociated more quickly from M2 receptors
BID→daily dosing
U+R→daily
G+T+A→BID
I-A→QID

SAMA-SABA combinations
QID

LAMA-LABA combinations
U-V→daily
G-FF+TB-O+I-GI→BID

AE: poorly absorbed (anticholinergic)
dry mouth
bitter/metallic taste (ipatropium)
small increase in CV events (ipatropium)
urinary sx

29
New cards

Methylxanthines

MX: theophylline

MOA: non-selective phosphodiesterase inhibitors→weak bronchodilation
requires high plasma concentrations

ROA: daily
IR→q6-8 hrs
12-hr ER→q12 hrs
24-hr ER→daily
tolerated x 3 days→increase dose→tolerate 3 more days→increase dose

I: COPD

AE: many pts can’t tolerate
RF→overdose
atrial+ventricular arrhythmias
grand mal convulsions
headaches
insomnia
nausea
heartburn

CI: erythromycin
ciprofloxacin
allopurinol
cimetidine
fluvoxamine
zileuton

30
New cards

Inhaled Corticosteroids

MX:
ICS
flunisolide
cicloesonide
fluticasone furoate
mometasone
fluticasone propionate
budesonide
beclomethasone

LAMA-ICS combination
fluticasone propionate-salmeterol
budenoside-formoterol fumarate dihydrate
mometasone furoate-formoterol fumarate dihydrate
fluticasone furoate-vilaterol

LAMA-LABA-ICS combination
umeclidinium-fluticasone furoate-vilanterol
glycopyrrolate-formoterol-budesonide

MOA:
anti inflammatory
blocks late reaction to allergen
reduces airway hyper-responsiveness

inhibits:
cytokine production
adhesion
protein activation
inflammatory cell migration+activation

reverse beta-2 receptor downregulation
inhibits microvascular leakage

I:
ICS
COPD exacerbation+hospitalization
2+ moderate COPD exacerbations/year
eosinophils 300+ cells/microL
concomitant asthma
asthma hx

LAMA-ICS combination
COPD
asthma

LAMA-LABA-ICS combination
COPD

ROA:
ICS
inhalation

LAMA-ICS combination
FP-S+B-FFD+MF-FFD→BID
FF-V→daily

LAMA-LABA-ICS combination
U-FF-V→daily
G-F-B→BID

AE: PO candidiasis
hoarse voice
skin bruising
pneumonia

CI: repeat pneumonia
eosinophils u100 cells/microL
mycobacterial infxn hx

31
New cards

PO Glucocorticoids

MOA: reduce tx failure rate
reduce relapse rate
improve lung fxn
decrease breathlessness

I: acute exacerbations in hospitalized pts
ED
short-term

ROA: duration→5-7 days

AE: many AEs
no benefits
high rate of systemic complications

32
New cards

Phosphodiesterase-4 Inhibitors

MX: roflumilast

MOA: inhibits breakdown of intracellular cyclic AMP→reduces inflammation+improve lung fxn+decreases COPD exacerbation risk

I: severe-very severe COPD (predicted FEV1 u50%)
chronic bronchitis
hx of frequent COPD exacerbations

ROA: daily x 4 weeks→daily

AE: diarrhea
nausea
reduced appetite
weight loss
abdominal pain
sleep disturbance
headache
suicidality

CI: underweight
depression

33
New cards

Mucolytics

MX: carbocystiene
N-acetylcysteine

MOA: reduce sputum viscosity
promote expectoration
regular use→reduce exacerbation+modestly improve health status

I: COPD+no ICS

34
New cards

Antibiotics (For COPD)

MX: azythromycin
erythromycin

MOA: anti-inflammatory properties
may reduce rate of exacerbations
not used for antimicrobial properties

I: COPD exacerbation-prone pts

ROA:
A
daily x 1 year
TIW x 1 year
E→BID x 1 year

35
New cards

COPD NP Tx

pulmonary rehabilitation

self-management

integrated care programs

physical activity

exercise training

nutritional suport

O2 tx+ventilatory support

36
New cards

COPD Exacerbations Tx

NP: acute respiratory failure+no CIs→non-invasive mechanical ventilation

MX: nebulizer/inhaler SABA q4-6h
nebulizer/inhaler SABA+SAMA q4-6h
nebulizer/inhaler SAMA q4-6h

severe exacerbations→systemic corticosteroids→IV methylprednisolone q8h
-less severe→PO
-no more than 5 days

PO azithromycin daily x 3 days
PO azythromycin x taper up

37
New cards

Nebulizers

jet nebulizers

  • compressed gas passes through a jet with aerosolized mx

  • 10-20%→deposited in respiratory tract

  • I→bronchodilator tx

mesh nebulizers

  • multiple apertures to produce aerosol

  • up+down movement through mesh→inhale mx

  • vibrating mesh/horn

  • expensive

  • not for bronchodilator tx

ultrasonic nebulizers

  • uses pizoelectric crystal

  • vibrates at high frequency→creates inhalable droplets


38
New cards

Pressurized Metered Dose Inhalers (pMDI) Key Components+Benefits+Limitations

key components
canister
propellant (HFA)
mx formulation
metering valve
actuator

benefits

  • small size

  • portability

  • convenience

  • multi dose capability

  • rapid dose delivery

  • contents protected from contamination

limitations

  • mx delivery depends on pt technique

  • misuse→suboptimal lung deposition of mx


39
New cards

pMDI Technique

process

  1. prime the inhaler per manufacturer instructions

  2. shake inhaler to mix expectorant+medication

  3. take cap off mouthpiece+examine for any foreign objects

  4. exhale through mouth→push out all air from lungs→close lips around mouthpiece+form a tight seal

  5. while pushing down on canister inhale deeply+slowly at same time

  6. hold breath for 10 seconds or as long as possible

  7. exhale slowly

compared with breath-actuated MDI

  • releases mist of mx when person inhales

  • must seal lips around mouthpiece+breathe in deeply with a steady amount of force


40
New cards

Spacers+Valved Holding Chambers

both direct mx into lungs+improve pt technique

spacer

  • simple tube/extension

  • contains aerosol plume actor pMDI actuation

valved holding chambers

  • extension device than contains one-way valves to hold aerosol until inhalation

  • more useful than spacer in poor hand-breath coordination pts

  • decreases oropharyngeal deposition

  • used with pMDI

recommended use:
-children
-adults with difficulty with technique

41
New cards

Dry Powder Inhaler

MX: aerolizer
diskus
ellipta
flexhaler
handihaler
neohaler
pressair
rotahaler
turbuhaler
twisthaler
handihaler

creates aerosol when inhaled air is drawn through a powdered mx
-powder contains micronized mx particles
-must be disaggregated to under 5 microns

requires high inspiratory flow (30-120L/min) to appropriately disaggregate particles+overcome device resistance

devices requiring more/less inspiratory flow
highest resistance→handihaler
lowest resistance→ellipta

avoid use
very young/ill children
weak pts
older pts
altered mental status pts

42
New cards

Rescue Inhaler+Maintenance Inhalers

rescue inhaler+LABA

  • PRN

  • tx acute sxs
    -wheezing
    -dyspnea
    -etc.

  • short-acting→x4-6 hrs

maintenance inhaler+LABA

  • daily

  • prophx→acute sxs/exacerbations

  • long-acting→ x12-24 hrs